Reckitt Benckiser (OTCMKTS:RBGLY) has received an average rating of “Hold” from the eight analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company.
Several analysts recently weighed in on the stock. Deutsche Bank reiterated a “buy” rating on shares of Reckitt Benckiser in a report on Friday, March 23rd. Credit Suisse Group reiterated a “neutral” rating on shares of Reckitt Benckiser in a report on Tuesday, February 20th. Zacks Investment Research cut shares of Reckitt Benckiser from a “hold” rating to a “sell” rating in a report on Wednesday, March 14th. Finally, Societe Generale upgraded shares of Reckitt Benckiser from a “hold” rating to a “buy” rating in a report on Thursday, March 22nd.
OTCMKTS:RBGLY traded up $0.02 during trading hours on Tuesday, hitting $16.07. The company had a trading volume of 1,191,082 shares, compared to its average volume of 859,473. The stock has a market cap of $56.52 billion, a P/E ratio of 22.96, a price-to-earnings-growth ratio of 4.10 and a beta of 0.98. Reckitt Benckiser has a 52 week low of $15.14 and a 52 week high of $21.79. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.85.
About Reckitt Benckiser
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amop茅, and Strepsils brand names.